BioSpecifics Technologies (BSTC) versus Its Rivals Head to Head Review
BioSpecifics Technologies (NASDAQ: BSTC) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare BioSpecifics Technologies to related businesses based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
This table compares BioSpecifics Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioSpecifics Technologies Competitors||-5,189.81%||-162.78%||-35.24%|
55.9% of BioSpecifics Technologies shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 21.5% of BioSpecifics Technologies shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
BioSpecifics Technologies has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, BioSpecifics Technologies’ rivals have a beta of 0.44, meaning that their average stock price is 56% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for BioSpecifics Technologies and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioSpecifics Technologies Competitors||924||3346||11852||237||2.70|
BioSpecifics Technologies currently has a consensus target price of $65.00, indicating a potential upside of 48.37%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.70%. Given BioSpecifics Technologies’ stronger consensus rating and higher probable upside, research analysts clearly believe BioSpecifics Technologies is more favorable than its rivals.
Valuation and Earnings
This table compares BioSpecifics Technologies and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioSpecifics Technologies||$26.25 million||$11.37 million||27.55|
|BioSpecifics Technologies Competitors||$290.27 million||$35.99 million||58.76|
BioSpecifics Technologies’ rivals have higher revenue and earnings than BioSpecifics Technologies. BioSpecifics Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
BioSpecifics Technologies beats its rivals on 9 of the 13 factors compared.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.